Exercise CapacityPhase 4NCT06638671
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity
A Phase 4 study testing Metformin Hydrochloride in people with Exercise Capacity and Metformin, run by University of Virginia at 1 site in United States.
Trial summary
Metformin is the most prescribed blood sugar (glucose)-lowering medication for patients diagnosed with type 2 diabetes mellitus (T2DM). Metformin stimulates glucose uptake in skeletal muscle similar to the effects of exercise, though, some studies report that metformin may decrease exercise capacity. Read more about this study
- Who is it for?
- Ages 18 to 30 yearsHealthy volunteers can take part
- Conditions the study is for
- Exercise Capacity, Metformin
- What is being tested?
- Metformin Hydrochloride
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 14 participants
- Where
- 1 siteUnited States
- Study dates
- 31 Jan 2025to 12 Mar 2026
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- 18-30 years old
- Metformin-naïve
- BMI < 30 kg/m2
- Recreationally active (≥ 3 days/week of exercise)
- Females must be premenopausal and report normal menstrual cycles
- Willingness and ability to comply with scheduled visits and study procedures.
Who cannot join
- History of cardiometabolic disease, such as type 1 or type 2 diabetes
- Smoking (must have quit at least 6 mos prior)
- Use of medication that significantly alters glucose regulation (e.g., metformin, insulin, GLP-1 receptor agonists, SGLT-2 inhibitors, biguanides)
- Severe liver or kidney disease, or medications to treat liver or kidney disease
- Pregnant, breastfeeding, or plans to become pregnant during study period
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Virginia
Charlottesville, Virginia, 22903
About this study
Official title: Short-Term Metformin Use in Young, Healthy Adults: Impacts on the Blood Lactate Response to Exercise and Time-to-exhaustion in a Placebo-controlled, Crossover Study
Metformin is the most prescribed blood sugar (glucose)-lowering medication for patients diagnosed with type 2 diabetes mellitus (T2DM). Metformin stimulates glucose uptake in skeletal muscle similar to the effects of exercise, though, some studies report that metformin may decrease exercise capacity.
The main question this study looks to answer is:
- Does metformin alter exercise capacity?
Participants will:
- Complete 5 exercise tests on a stationary bike.
- Undergo a body composition test.
- Take metformin and placebo.
- Complete food and symptom logs.
The researchers hypothesize that:
- Metformin will reduce aerobic capacity.
Read the detailed description
Metformin, a potent biguanide, is the most prescribed glucose-lowering medication for patients newly diagnosed with type 2 diabetes mellitus (T2DM). Metformin has purported utility for various conditions such as aging, autoimmune conditions, and cancer, however, the primary use of metformin is for blood glucose reduction via decreased glucose production in the liver (increased glycogenesis, decreased glycogenolysis and gluconeogenesis), reduced glucose absorption in the gut, and enhanced insulin-independent skeletal muscle glucose uptake. The effect of metformin within skeletal muscle is the focus of this study.
The mechanism for improved metformin-mediated skeletal muscle glucose uptake involves the inhibition of complex 1 (NADH:ubiquinone oxidoreductase) in the mitochondrial electron transport chain (ETC). This leads to a reduced cellular energy charge, marked by a reduced ATP concentration and increased ratios of ADP:ATP and AMP:ATP. This energetic imbalance initiates phosphorylation of 5' adenosine monophosphate-activated protein kinase (AMPK), which in turn induces glucose transporter (GLUT4) translocation to the cell membrane and upregulates insulin-independent glucose uptake by skeletal muscle fibers. This cellular energy imbalance and subsequent AMPK signaling cascade is similar to stress elicited by exercise. However, during exercise, the energy imbalance is created by increased ATP utilization from skeletal muscle contraction rather than incomplete glucose metabolism (less ATP per glucose) and an increased reliance on glycolysis.
Exercise training is considered the gold standard approach to enhanced cardiorespiratory fitness and peripheral insulin sensitivity across the lifespan. Metformin also benefits glycemic control and reduces cardiovascular risk. Although the evidence is not conclusive, metformin has been shown to potentially decrease exercise capacity in healthy subjects and those with metabolic syndrome. Importantly, due to the increased reliance on anaerobic metabolism, metformin may reduce the lactate threshold (LT) and lactate turn point (LTP), which are strong predictors of perception of effort, submaximal fitness, and endurance performance. Given cardiorespiratory fitness, strength, glucose control, and insulin sensitivity are predictors of disease, disability, and all-cause mortality, it is important to determine the effects of metformin on cardiorespiratory fitness and physical function.
While these mechanisms of metformin in skeletal muscle are compelling for glucose regulation, there is significant variation in the literature on the effects of metformin on exercise capacity, largely due to differences in dosing (e.g., ~50-500 mg/kg) and exercise intervention design (e.g., acute vs. short-term or chronic exercise and/or submaximal vs. maximal exercise intensity). A recent meta-analysis by found that because previous studies have predominantly used exercise intensities well below VO2max, metformin does not appear to affect maximal oxygen uptake in healthy volunteers; metformin may only alter exercise capacity at high or near-maximal work rates. Thus, there is a lack of data on the effects of metformin on lactate threshold, blood lactate clearance, and exercise-induced fatigue.
Data from this study will provide valuable insight into the effects of metformin compared to placebo on exercise capacity at near-maximal work rates in young, healthy adults. While some studies have examined metformin's impact on exercise performance, these tend to be studies where exercise intensity was well below maximal effort, in highly trained cyclists, or in clinical populations (e.g., individuals with T2DM). Importantly, the results from this study may lead healthy individuals to adjust exercise protocols to accommodate for the decline in performance along with an increased perceived exertion that may accompany metformin consumption. Moreover, this study may fill the gap in literature on a slightly longer timeline for metformin ingestion effects on exercise capacity compared to acute consumption, which may have a more profound impact on cardiorespiratory fitness and capacity over time.
- Conditions
- Exercise Capacity, Metformin
- Being tested
- Metformin Hydrochloride, Placebo
- Keywords
- Exercise capacity, Metformin, Lactate threshold
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Metformin HydrochlorideDrug
Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
PlaceboDrug
Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
| Study group | Role | What they receive |
|---|---|---|
| Metformin (MET) | Experimental | At the end of the screening visit, participants will be randomized to either Condition A or Condition B (MET or PL first). Participants will begin the 19-day treatment phase of study the day after screening.
During each treatment phase, participants will consume metformin as follows: 1x500 mg tablet/day for 5 days, 2x500 mg tablets/day for 5 days, and 3x500 mg tablets/day (or maximally tolerated dosage) for 9 days.
Participants will then complete a VO2peak/LT test on day 16, rest for 48 hours, then complete a time-to-exhaustion test (day 19) during the final days of the treatment phase. After the time-to-exhaustion test, participants will begin the placebo treatment phase. Receives: Drug: Metformin Hydrochloride |
| Placebo (PL) | Placebo comparator | At the end of the screening visit, participants will be randomized to either Condition A or Condition B (MET or PL first). Participants will begin the 19-day treatment phase of study the day after screening.
During each treatment phase, participants will consume placebo as follows: 1x500 mg tablet/day for 5 days, 2x500 mg tablets/day for 5 days, and 3x500 mg tablets/day (or maximally tolerated dosage) for 9 days.
Participants will then complete a VO2peak/LT test on day 16, rest for 48 hours, then complete a time-to-exhaustion test (day 19) during the final days of the treatment phase. After the time-to-exhaustion test, participants will begin the metformin treatment phase. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Exercise capacity
Exercise capacity will be measured by absolute and relative VO2peak
Measured: 6 weeks
Lactate threshold
Lactate threshold (LT) will be determined by power output immediately before the curvilinear increase in lactate concentration
Measured: 6 weeks
VO2 at Lactate threshold
VO2 at LT denoted as VO2 obtained at the same power output as LT
Measured: 6 weeks
Lactate turnpoint (LTP)
LTP will be determined by the power output obtained immediately before the second sharp increase in blood lactate concentration
Measured: 6 weeks
Maximal power output
Maximal power output (watts) during exercise
Measured: 6 weeks
Secondary outcomes (3)
Respiratory exchange ratio (RER)
RER will be determined during exercise as the ratio of expired CO2 and inspired O2, as an estimate of substrate utilization
Measured: 6 weeks
Ventilation (VE)
Minute ventilation collected during exercise
Measured: 6 weeks
Maximal fat oxidation (Fatmax)
Maximal amount of fat oxidized during exercise
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2024
- Study start31 Jan 2025
- Primary completion12 Mar 2026
- Study completion12 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Exercise CapacityStudies of the same condition, open and under way.
- More trials run by University of VirginiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Randomized, double-blind, placebo-controlled crossover design
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 14 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Virginia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jason Allen, University of Virginia
- Investigators
- Jason D Allen, PhD, Principal investigator, University of Virginia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06638671
- Sponsor's protocol ID
- HSR240014
- Status last verified
- Jun 2026
- First submitted
- 23 Sep 2024
- Last updated
- 17 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Short-Term Metformin Use in Young, Healthy Adults: Impacts on the Blood Lactate Response to Exercise and Time-to-exhaustion in a Placebo-controlled, Crossover Study
- ClinicalTrials.gov ID
- NCT06638671
- Acronym / sponsor ID
- HSR240014
- Conditions
- Exercise Capacity, Metformin
- Keywords
- Exercise capacity, Metformin, Lactate threshold
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 14 participants (actual)
- Lead sponsor
- University of VirginiaUniversity, hospital or other
- Study start
- 31 Jan 2025 (actual)
- Primary completion
- 12 Mar 2026 (actual)
- Study completion
- 12 Mar 2026 (actual)
- First posted
- 15 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Metformin is the most prescribed blood sugar (glucose)-lowering medication for patients diagnosed with type 2 diabetes mellitus (T2DM). Metformin stimulates glucose uptake in skeletal muscle similar to the effects of exercise, though, some studies report that metformin may decrease exercise capacity.
The main question this study looks to answer is:
- Does metformin alter exercise capacity?
Participants will:
- Complete 5 exercise tests on a stationary bike.
- Undergo a body composition test.
- Take metformin and placebo.
- Complete food and symptom logs.
The researchers hypothesize that:
- Metformin will reduce aerobic capacity.
Detailed description
Metformin, a potent biguanide, is the most prescribed glucose-lowering medication for patients newly diagnosed with type 2 diabetes mellitus (T2DM). Metformin has purported utility for various conditions such as aging, autoimmune conditions, and cancer, however, the primary use of metformin is for blood glucose reduction via decreased glucose production in the liver (increased glycogenesis, decreased glycogenolysis and gluconeogenesis), reduced glucose absorption in the gut, and enhanced insulin-independent skeletal muscle glucose uptake. The effect of metformin within skeletal muscle is the focus of this study.
The mechanism for improved metformin-mediated skeletal muscle glucose uptake involves the inhibition of complex 1 (NADH:ubiquinone oxidoreductase) in the mitochondrial electron transport chain (ETC). This leads to a reduced cellular energy charge, marked by a reduced ATP concentration and increased ratios of ADP:ATP and AMP:ATP. This energetic imbalance initiates phosphorylation of 5' adenosine monophosphate-activated protein kinase (AMPK), which in turn induces glucose transporter (GLUT4) translocation to the cell membrane and upregulates insulin-independent glucose uptake by skeletal muscle fibers. This cellular energy imbalance and subsequent AMPK signaling cascade is similar to stress elicited by exercise. However, during exercise, the energy imbalance is created by increased ATP utilization from skeletal muscle contraction rather than incomplete glucose metabolism (less ATP per glucose) and an increased reliance on glycolysis.
Exercise training is considered the gold standard approach to enhanced cardiorespiratory fitness and peripheral insulin sensitivity across the lifespan. Metformin also benefits glycemic control and reduces cardiovascular risk. Although the evidence is not conclusive, metformin has been shown to potentially decrease exercise capacity in healthy subjects and those with metabolic syndrome. Importantly, due to the increased reliance on anaerobic metabolism, metformin may reduce the lactate threshold (LT) and lactate turn point (LTP), which are strong predictors of perception of effort, submaximal fitness, and endurance performance. Given cardiorespiratory fitness, strength, glucose control, and insulin sensitivity are predictors of disease, disability, and all-cause mortality, it is important to determine the effects of metformin on cardiorespiratory fitness and physical function.
While these mechanisms of metformin in skeletal muscle are compelling for glucose regulation, there is significant variation in the literature on the effects of metformin on exercise capacity, largely due to differences in dosing (e.g., ~50-500 mg/kg) and exercise intervention design (e.g., acute vs. short-term or chronic exercise and/or submaximal vs. maximal exercise intensity). A recent meta-analysis by found that because previous studies have predominantly used exercise intensities well below VO2max, metformin does not appear to affect maximal oxygen uptake in healthy volunteers; metformin may only alter exercise capacity at high or near-maximal work rates. Thus, there is a lack of data on the effects of metformin on lactate threshold, blood lactate clearance, and exercise-induced fatigue.
Data from this study will provide valuable insight into the effects of metformin compared to placebo on exercise capacity at near-maximal work rates in young, healthy adults. While some studies have examined metformin's impact on exercise performance, these tend to be studies where exercise intensity was well below maximal effort, in highly trained cyclists, or in clinical populations (e.g., individuals with T2DM). Importantly, the results from this study may lead healthy individuals to adjust exercise protocols to accommodate for the decline in performance along with an increased perceived exertion that may accompany metformin consumption. Moreover, this study may fill the gap in literature on a slightly longer timeline for metformin ingestion effects on exercise capacity compared to acute consumption, which may have a more profound impact on cardiorespiratory fitness and capacity over time.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- Randomized, double-blind, placebo-controlled crossover design
| Arm | Type | Receives |
|---|---|---|
| Metformin (MET) | Experimental | Drug: Metformin HydrochlorideAt the end of the screening visit, participants will be randomized to either Condition A or Condition B (MET or PL first). Participants will begin the 19-day treatment phase of study the day after screening. During each treatment phase, participants will consume metformin as follows: 1x500 mg tablet/day for 5 days, 2x500 mg tablets/day for 5 days, and 3x500 mg tablets/day (or maximally tolerated dosage) for 9 days. Participants will then complete a VO2peak/LT test on day 16, rest for 48 hours, then complete a time-to-exhaustion test (day 19) during the final days of the treatment phase. After the time-to-exhaustion test, participants will begin the placebo treatment phase. |
| Placebo (PL) | Placebo comparator | Drug: PlaceboAt the end of the screening visit, participants will be randomized to either Condition A or Condition B (MET or PL first). Participants will begin the 19-day treatment phase of study the day after screening. During each treatment phase, participants will consume placebo as follows: 1x500 mg tablet/day for 5 days, 2x500 mg tablets/day for 5 days, and 3x500 mg tablets/day (or maximally tolerated dosage) for 9 days. Participants will then complete a VO2peak/LT test on day 16, rest for 48 hours, then complete a time-to-exhaustion test (day 19) during the final days of the treatment phase. After the time-to-exhaustion test, participants will begin the metformin treatment phase. |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- 18-30 years old
- Metformin-naïve
- BMI < 30 kg/m2
- Recreationally active (≥ 3 days/week of exercise)
- Females must be premenopausal and report normal menstrual cycles
Key exclusion criteria (5 listed)
- History of cardiometabolic disease, such as type 1 or type 2 diabetes
- Smoking (must have quit at least 6 mos prior)
- Use of medication that significantly alters glucose regulation (e.g., metformin, insulin, GLP-1 receptor agonists, SGLT-2 inhibitors, biguanides)
- Severe liver or kidney disease, or medications to treat liver or kidney disease
- Pregnant, breastfeeding, or plans to become pregnant during study period
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Metformin HydrochlorideParticipants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase. | Drug | Metformin (MET) |
| PlaceboParticipants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase. | Drug | Placebo (PL) |
Primary outcome
Exercise capacity
Time frame: 6 weeks
Exercise capacity will be measured by absolute and relative VO2peak
Lactate threshold
Time frame: 6 weeks
Lactate threshold (LT) will be determined by power output immediately before the curvilinear increase in lactate concentration
VO2 at Lactate threshold
Time frame: 6 weeks
VO2 at LT denoted as VO2 obtained at the same power output as LT
Lactate turnpoint (LTP)
Time frame: 6 weeks
LTP will be determined by the power output obtained immediately before the second sharp increase in blood lactate concentration
Maximal power output
Time frame: 6 weeks
Maximal power output (watts) during exercise
3 secondary outcomes
Respiratory exchange ratio (RER)
Time frame: 6 weeks
Ventilation (VE)
Time frame: 6 weeks
Maximal fat oxidation (Fatmax)
Time frame: 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Exercise Capacity
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Recruiting
Time of Exercise Re-training With Chronic Obstructive Pulmonary Disease (COPD)
Respiratory Diseases
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life
Heart Failure With Preserved Ejection Fraction, Iron Deficiencies
Not yet recruiting
Comparison of Functional Inspiratory Muscle Training and Combined Exercise Training in Individuals With Type 2 Diabetes
Type 2 Diabetes Mellitus
Active, not recruitingPhase 2
Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD
COPD (Chronic Obstructive Pulmonary Disease)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jason D Allen, PhD principal investigator
University of Virginia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Metformin Hydrochloride in people with Exercise Capacity and Metformin, run by University of Virginia at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Exercise capacity (time frame: 6 weeks). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2026.